Literature DB >> 21707384

Changing end points in breast-cancer drug approval--the Avastin story.

Ralph B D'Agostino1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21707384     DOI： 10.1056/NEJMp1106984

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

Review 1.  Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Authors:  Michael J Demeure; Kimberly J Bussey; Lawrence S Kirschner
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  Role of randomized phase III trials in an era of effective targeted therapies.

Authors:  Manish R Sharma; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

3.  Can intensive longitudinal monitoring of individuals advance cancer research?

Authors:  C Anthony Blau
Journal:  Oncologist       Date:  2012-04-20

4.  Incorporating biomarkers into clinical trial designs: points to consider.

Authors:  Edward Bradley
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

5.  The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.

Authors:  Rajat Banerjee; Elizabeth A Van Tubergen; Christina S Scanlon; Robert Vander Broek; Joel P Lints; Min Liu; Nickole Russo; Ronald C Inglehart; Yugang Wang; Peter J Polverini; Keith L Kirkwood; Nisha J D'Silva
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

6.  How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.

Authors:  Stacie B Dusetzina; Shellie Ellis; Rachel A Freedman; Rena M Conti; Aaron N Winn; James D Chambers; G Caleb Alexander; Haiden A Huskamp; Nancy L Keating
Journal:  J Oncol Pract       Date:  2015-06-09       Impact factor: 3.840

Review 7.  Clinical advances in the development of novel VEGFR2 inhibitors.

Authors:  Caterina Fontanella; Elena Ongaro; Silvia Bolzonello; Michela Guardascione; Gianpiero Fasola; Giuseppe Aprile
Journal:  Ann Transl Med       Date:  2014-12

8.  Design and conduct of intervention-based research among cancer survivors.

Authors:  Kathleen Y Wolin; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

9.  The evolution of Reference Drug Lists and Clinical Practice Guidelines in the public health system of a middle-income country.

Authors:  Israel Rico-Alba; Albert Figueras
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  Targeting angiogenesis in metastatic breast cancer.

Authors:  Sangeetha Reddy; Michael Raffin; Virginia Kaklamani
Journal:  Oncologist       Date:  2012-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.